Abbott CFO uses 388 shares to cover tax at $110.36

Abbott’s EVP and CFO used 388 shares to cover option exercise or tax obligations and now reports direct and indirect ownership totaling several share blocks.

Rhea-AI Filing Summary

ABBOTT LABORATORIES (ABT) executive vice president and chief financial officer Philip P. Boudreau reported a Form 4 showing that on September 1, 2026, 388 common shares were disposed of at $110.36 per share to satisfy exercise price or tax liability obligations. After this withholding, he holds 70,784 common shares directly, plus indirect holdings of 9,332 shares in the Abbott Laboratories Stock Retirement (Profit Sharing) Trust and 2,200 shares held by his spouse. No Rule 10b5-1 trading plan is affirmed.

Insider Trade Summary

Exercise Price or Tax Liability: 388 shares

Exercise Price or Tax Liability 3 txns

Insider Boudreau Philip P

Role EVP AND CFO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common shares without par value	388	$110.36	$43K
holding	Common shares without par value F1	--	--	--
holding	Common shares without par value	--	--	--

Holdings After Transaction: Common shares without par value — 70,784 shares (Direct); Common shares without par value — 9,332 shares (Indirect, Profit Sharing Trust); Common shares without par value — 2,200 shares (Indirect, By Spouse)

Footnotes (1)

1. F1. Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2026.

Key Figures

Shares delivered/withheld for exercise price or tax liability: 388 shares Price per share for code F disposition: $110.36 per share Direct common shares after transaction: 70,784 shares +2 more

5 metrics

Shares delivered/withheld for exercise price or tax liability 388 shares Common shares disposed of on September 1, 2026 under transaction code F

Price per share for code F disposition $110.36 per share Value used for the 388-share exercise-price-or-tax-liability disposition

Direct common shares after transaction 70,784 shares Direct holdings of Philip P. Boudreau following the September 1, 2026 event

Indirect shares in Profit Sharing Trust 9,332 shares Balance in Abbott Laboratories Stock Retirement Trust as of September 1, 2026

Indirect shares held by spouse 2,200 shares Indirect ownership reported as held by spouse after the transaction

Key Terms

Payment of exercise price or tax liability, Profit Sharing Trust, Common shares without par value

3 terms

Payment of exercise price or tax liability financial

"Payment of exercise price or tax liability by delivering or withholding securities"

Profit Sharing Trust financial

"Indirect ownership nature described as Profit Sharing Trust"

Common shares without par value financial

"Security title listed as Common shares without par value"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did ABT’s EVP and CFO Philip P. Boudreau report on this Form 4?

He reported that on September 1, 2026, 388 common shares of Abbott Laboratories were disposed of to provide payment of exercise price or tax liability by delivering or withholding securities, rather than as an open-market sale.

How many Abbott Laboratories (ABT) shares were used to cover obligations, and at what price?

A total of 388 common shares were delivered or withheld at a price of $110.36 per share to satisfy exercise price or tax liability related to equity awards.

How many ABT shares does Philip P. Boudreau hold directly after this transaction?

Following the September 1, 2026 transaction, Philip P. Boudreau holds 70,784 common shares of Abbott Laboratories in direct ownership.

What indirect ownership in Abbott Laboratories (ABT) does Philip P. Boudreau report?

He reports indirect ownership of 9,332 shares held in a Profit Sharing Trust (the Abbott Laboratories Stock Retirement Trust, as of September 1, 2026) and 2,200 shares held by his spouse.

Was the ABT Form 4 transaction made under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked, and no footnote indicates that the September 1, 2026 transaction was made under a Rule 10b5-1 trading plan.

Did Philip P. Boudreau report any derivative exercises of ABT securities in this filing?

No. The filing’s summary shows no derivative transactions and no exercises of options or other derivative securities; it reports only a code F disposition and updated share holdings.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 06:06 PM EDT Accepted by SEC EDGAR 09/03/2026 - 06:02 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boudreau Philip P

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP AND CFO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	09/01/2026		F		388	D	$110.36	70,784	D
Common shares without par value								9,332(1)	I	Profit Sharing Trust
Common shares without par value								2,200	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2026.

	/s/ Philip P. Boudreau, by Jessica H. Paik, Attorney-in-Fact	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)